Eversana, Evoke Pharma partner on nasal drug for patients with diabetic gastroparesis
Life-sciences commercialization solutions firm Eversana worked with Evoke Pharma, a specialty pharma firm centered on gastrointestinal (GI) disease treatments, on Gimoti (metoclopramide) nasal spray, intended to relieve symptoms of adult patients suffering from acute and diabetic gastroparesis. By bypassing the GI tract, the drug helps avoid problems associated with gastric emptying challenges, which could lead to patients vomiting their medications.
David Gonyer, president and CEO of Evoke Pharma, told Outsourcing-Pharma that Eversana contributed helpful experience and knowledge to the commercialization and launch of the drug, and their team guided forecasting, pricing, go-to-market strategy, brand positioning and more.
“Their distribution network which is uniquely designed to meet our needs, coupled with their Patient Services team which offers experts that truly understand the needs of patients; Eversana offers everything we needed to bring Gimoti to market,” Gonyer said. “They helped us add a sales team that is currently connecting with healthcare providers to help them understand the benefits of Gimoti for patients with diabetic gastroparesis."
Henry Parkman, director of the Gastroenterology Motility Laboratory at Temple University’s School of Medicine, said diabetic gastroparesis patients suffer from erratic absorption of orally administered drugs, which Gimoti helps to avoid.
“Unlike oral medications, Gimoti is administered nasally, bypassing the need for absorption in the GI system, allowing the drug to enter the bloodstream directly and avoiding the problem of unpredictable stomach emptying,” Parkman said. “For these patients suffering from debilitating symptoms such as nausea, abdominal pain, bloating, early satiety, and vomiting, Gimoti is an important alternative to the current standard of care to help those that suffer from this disease.”
Gonyer added, “Gimoti fills a major treatment gap by providing the current standard of care treatment through a non-oral delivery. With the support of an integrated commercial team from EVERSANA, we are confident in our ability to address the large and growing market opportunity.”
Eversana CEO Jim Lang commented, “Evoke’s innovative approach is a welcome advancement that has the ability to change the continuum of care for treatment of adults suffering from the symptoms of diabetic gastroparesis. Powered by a full commercialization engine, a trained sales team will be immediately deployed to offer this novel approach to their targeted physician base; patients will then get the full benefit of our access, distribution and adherence services, optimized by real-time analytics and actions.”
